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Abstract 
Background 
Hematopoietic stem cell transplantation (HSCT) has been proposed as a therapeutic option for patients 
with Systemic Lupus Erythematosus (SLE) refractory to standard therapy. This therapeutic approach has 
been applied to other severe autoimmune diseases refractory to standard therapy with promising results. 
Aim 
To systematically review the literature and  analyze the available evidence on HSCT therapy in patients with 
SLE and antiphospholipid syndrome (APS), with a focus on therapy efficacy and occurrence of adverse 
events.     
Methods 
A detailed literature search, applied to Ovid MEDLINE, In-Process and Other Non-Indexed Citation and Ovid 
Medline 1986 to 2014, has been developed a priori to identify articles that reported findings from clinical 
and laboratory studies that investigated the effect of HCT in patients with SLE. 
Results 
25 studies met all inclusion criteria, including a total of 279 SLE patients; of those, 54 patients also fulfilled 
the classification criteria of APS. The majority of the studies reported an improvement after HSCT in terms 
of diseases activity control (assessed with SLEDAI, or time-free from diseases) or overall survival. However, 
one study reported no net benefit of HSCT when compared to immunosuppression alone. One 
retrospective study reported an overall survival at 5 years of 81% in 28 SLE patients. 
Of note, 5 cases (9.3%) of aPL negativization were reported after HSCT in the APS patients. When 
combining these studies and analyzing these patients with APS, 32 out of 44 (73%) were able to discontinue 
anticoagulation after HSCT. Our findings also demonstrate a total of 86 infections in the pool of patients 
(30.8%), 3 of which resulted in the death of the patient (1.3%). We observed an annual incidence of 
infection of 11.9% with a mean follow up of 36.2 months.   
 
Conclusion 
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Preliminary results of HSCT as a therapeutic option for SLE  appear promising. Further studies are 
warranted in order to assess the safety of the procedure for both the occurrence of secondary autoimmune 
disease and the rate of infection. However, the rate of adverse effects confines this option to very selected 
cases of SLE patients resistant or refractory to standard approaches.  
 
Highlights 
 Hematopoietic stem cell transplantation (HSCT) has been proposed with promising results as a 
therapeutic option for patients with severe autoimmune diseases refractory to standard therapy. 
 The rate of adverse effects confines HSCT to very selected cases of patients with Systemic Lupus 
Erythematosus resistant or refractory to standard approaches.  
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1.1 Introduction 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by a relapsing 
intermitting course with periods of flares, alternating periods of remission and by highly heterogeneous 
clinical manifestations with a multi-systemic involvement [1]. The management of SLE is based on non-
steroidal anti-inflammatory drugs, glucocorticoids (GC), hydroxychloroquine (HCQ) and immunosuppressive 
agents, as well as novel biotechnological therapies [2,3]. Although advances in the treatment of SLE have 
led to a significant improvement in the prognosis, SLE management remains challenging due to the adverse 
effects associated with conventional therapies and the occurrence of refractory disease.  
Hematopoietic stem cell transplantation (HSCT) has been proposed as an alternative therapeutic option for 
SLE patients refractory to standard therapy. The initial findings of remission of severe autoimmune disease 
were described in patients undergoing transplantation for a hematologic disease who also had a 
coincidental autoimmune disease[4–6]. Following these observations, this therapeutic approach has been 
applied to other severe autoimmune diseases refractory to standard therapy [7–10] and preliminary results 
of animal model studies have been promising [11,12]. Although the mechanism of remission of disease 
induced by HSCT is likely to be due to  intensive immune suppression, it may also play a role in modifying 
the immune system after transplant and thus leading to a prolonged period of remission. 
In this systematic review, we aim to analyze the available evidence on HSCT therapy in patients with SLE and 
antiphospholipid syndrome (APS), focusing on therapy efficacy and occurrence of adverse events.     
 
2.1 Patients and Methods 
Search and Study Selection 
A detailed literature search has been developed a priori to identify articles that reported findings from 
clinical and laboratory studies that investigated the effect of HCT in patients with SLE. Key words and 
subject terms included ("lupus vulgaris"[MeSH Terms] OR ("lupus"[All Fields] AND "vulgaris"[All Fields]) OR 
"lupus vulgaris"[All Fields] OR "lupus"[All Fields]) AND (("transplantation"[Subheading] OR 
"transplantation"[All Fields] OR "transplantation"[MeSH Terms]) OR (autologous[All Fields] AND 
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("hematopoietic stem cell transplantation"[MeSH Terms] OR ("hematopoietic"[All Fields] AND "stem"[All 
Fields] AND "cell"[All Fields] AND "transplantation"[All Fields]) OR "hematopoietic stem cell 
transplantation"[All Fields] OR ("hematopoietic"[All Fields] AND "cell"[All Fields] AND "transplantation"[All 
Fields]) OR "hematopoietic cell transplantation"[All Fields])) OR allogenic [All Fields]).  
The search strategy was applied to Ovid MEDLINE, In-Process and Other Non-Indexed Citation and Ovid 
Medline 1986 to 2014. References of applicable review articles and included studies were hand searched to 
identify other relevant studies. No search limits were applied. 
All published studies in manuscript form enrolling at least 1 patient with SLE undergoing auto- or allogenic 
HCT were included. We excluded abstracts not published as full manuscripts. Studies were independently 
reviewed by 2 authors (AL and AA). Any disagreements were resolved by consensus with other authors (SS, 
MR, MK). 
 
2.2 Data Collection 
Data were collected on study details, patient characteristics, clinical outcomes [overall survival (OS)] and 
harms [transplantation-related morbidity (TRM), disease relapse, autoantibodies seroconversion].  
Methodological quality utilizing a standardized data extraction form (Appendix 1). All data were 
independently extracted by 2 authors (AL and AA). Extracted data was verified for accuracy by another 
author (SS.). Methodological quality of included cohort studies was assessed using the Newcastle-Ottawa 
scale modified for single-arm cohort [13]. 
 
2.3 Data Analysis and Statistical Methods 
A proportion was calculated for each outcome. When possible, effect estimates from studies similar in 
terms of study design, included patients, interventions, and outcomes were pooled together. All results are 
reported as a proportion and a 95% confidence interval (CI). Heterogeneity was tested using the I2 test. An 
I2 above 30% was considered moderate heterogeneity and above 60% was considered high heterogeneity. 
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This systematic review is reported according to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses guidelines [14]. 
 
3.1 Results 
3.2 Search Results and Characteristics of Included Studies 
The search identified 2088 studies and 25 met all inclusion criteria [15–39]. The study selection process is 
reported in Figure 1. The use of allogenic/auto-HCT as rescue therapy for SLE/SAPS was assessed using data 
from 2 prospective [15,36], 10 retrospective studies [16-23, 34]and 13 case reports [24-33,35,37-39], for a 
total of 279 SLE patients. Of those, 54 patients also fulfilled the criteria of APS. The demographic and pre-
transplant clinical characteristics of the patients of included studies are reported in Tables 1 and 2 for 
patients with SLE and for SLE and APS, respectively.  
 
3.3 Control of disease activity  
3 out of 12 studies (2 prospective and 10 retrospective) assessed SLE activity with SLE Disease Activity Index 
(SLEDAI) [15,18,20]. Traynor and colleagues [15] reported that following HSCT a gradual, but marked, 
improvement in their cohort (<5 of SLEDAIin 12 patients). Gualandi et al. [18] demonstrated that 5 SLE 
patients had a decrease from 90 of cumulative SLEDAI index to 9 after transplant. Whereas another study 
[20] reported an overall decrease of SLEDAI after either immunosuppression alone or followed by 
transplant, with no statistical difference between the two groups.  
4 studies reported the disease-free survival in their cohort of patients [17,21,23,34]. Vanikar et al. [17] 
reported a disease-free interval of 7.35 months; Alchi et al. [23] showed a 5 year disease-free survival of 
29%; Song et al. [21] reported a progression-free survival of 64.7% (significantly higher than the control 
group), and finally Burt et al. [34] described a 50% disease-free survival at 5 years. 
 
3.4 aPL profile changes after HSCT  
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It is worth noting that studies that included SLE patients with APS (SAPS), reported 4 cases (7.4%) of aPL 
negativization after transplant and one study reported one case (1.9%) of aPL negativization after 
transplant in the first 6 months of follow-up. Statkute et al. [37] stated that 14 out of 22 SAPS patients were 
able to discontinue anticoagulation, while Burt et al. [34] described 18 out of 22 SAPS patients that were 
able to stop anticoagulation therapy after transplant.  No APS-related recurrences were described during 
the follow up (range=8-29 months). 
 
3.5 Overall-survival and mortality 
One retrospective study out of twelve total studies [23] reported the 5 years overall survival outcome. Alchi 
et al. [23] reported that in their 28 SLE patients the OS was 81% (5 patients died in 2 years after treatment, 
3 deaths were caused by infections, 1 progressive SLE and 1 caused by autoimmune haemolytic anaemia). 
Burt et al observed in 50 SLE patients a disease-free survival at 5 years of 50% (2 patients died after 
mobilization: one active lupus and one and one from mucormycosis). 
Song et al [21], reported that in their study of 17 SLE patients there were 2 deaths during the follow up 
period of 89 months. Paquini et al [22], with a cohort of 27 SLE patients, reported 8 deaths in a follow up 
period of 31 months and lastly Loh et al. [16] reported 3 deaths (2 SLE progression and the third following 
an accident). Furthermore, a case report described the death of all three of these patients due to transplant 
related complications during the follow up of 60 months [30].  
Twenty studies did not report deaths during their follow-up period (range= 7-70 months).  
When pooling together these studies, we observed an overall mortality of 8.3% with a mean follow-up of 
36.2 months.  
The heterogeneity between studies was high (I2 = 87%). 
The results describing outcomes, mortality and post-transplant clinical characteristics of the patients 
included in the analysis are summarized in Table 3 and 4. 
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3.6 Adverse events (AEs) 
In the 25 studies included, we observed a total of 86 infections (30.8%), 3 of which resulted in the death of 
the patient (1.3%). When pooling together the results from the studies analyzed, there was an annual 
incidence of infections of 11.9% with a mean follow up of 36.2 months.  Other adverse events included one 
case of allergic reaction to cyclophosphamide (0.4%), one case of fever related to G-CSF (0.4%), one Epstein 
Barr-associated lymphoproliferative disorder, one case of angular chelitis (0.4%), one case of factor VIII 
inhibitor hemorrhage (0.4%), two cases of secondary autoimmune diseases (0.7%) (one case of 
autoimmune hemolytic anemia that caused the death of the patient and one acquired hemophilia), three 
cases of bone pain (1.1%), three cases of mucositis (1.1%), three cases of (1.1%) enteropathy and finally 
three cases of severe hemorrhage (1.1%).  
 
4.1 Discussion 
Conventional treatments for SLE are typically directed against the adaptive immune response by limiting T 
and B cell activation, and/or lowering auto-antibody production. The rationale behind HSCT therapy in SLE 
is based on an initial phase of intensive immune-suppression to ablate the auto-reactive lymphocytes. The 
second phase is represented by a repopulation of the immune system by transplant with either autologous 
or allogeneic hematopoietic CD34+ progenitors cells, rescuing the patient from severe cytopenia and/or 
hematopoietic failure. It has been hypothesized that HSCT might permanently alter the immune system 
composition by losing T cell-mediated immune memory[4,9]. Although preliminary results described in the 
literature are promising, it is not clear whether HSCT alone with no intensive immunosuppression regimen 
could potentially induce remission in SLE patients. Currently, there is only one prospective phase I study 
that has investigated the safety and efficacy of immune suppression and HSCT in the treatment of SLE [15]. 
Although all patients included in the study demonstrated a gradual, but marked improvement (both in 
terms of clinical and laboratory parameters) it is important to note that phase I studies are not powered to 
determine efficacy of new experimental therapies.  
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Interestingly in the studies analysed, antibody negativization occurred in some of patients both for anti-DNA 
antibodies and antiphospholipid antibodies (aPL). Conversely, aPL negativization following 
immunosuppression therapy have been only occasionally described [40]. Besides, it is important to note 
that out of 44 APS reported cases for whom detailed therapy was provided, more than 70% were able to 
discontinue anticoagulation after HSCT [34,36–38].  
There are several limitations to the studies analysed: low number of patients of the studies included, 
potential publication bias with studies reporting only positive outcomes, heterogeneity in clinical 
presentation, and applied protocols of both immunosuppression and HSCT. It is also important to note a 
high number of infections and adverse events occurred in patients that underwent the protocol of high 
dose immune suppression regimen followed by HSCT. In fact, the protocol of intense immunosuppression 
applied to the treatment is intended to ablate the immune system to the point of marrow suppression, and 
the related adverse events can't be underestimated. 
A further obstacle to this therapy, as described by Daikeler and colleagues [41], is the development of 
secondary autoimmune diseases that may occur after  HSCT.   In this retrospective study, after autologous 
HSCT for primary autoimmune diseases, 29 of 347 patients analysed, developed at least one secondary 
autoimmune disease in the follow up period, and after allogeneic HSCT, 3 of 16 patients. Even though in our 
analysis only two cases of secondary autoimmune disease were described, Daikeler et al identified, after 
multivariate analysis, an initial diagnosis of SLE (P =0.019; hazard ratio=3.21; 95% confidence interval, 1.21-
8.48) is significant risk factor for developing a secondary autoimmune disease after HSCT.  
 
5.1 Conclusion 
Despite the limitations of the studies analysed, the preliminary results of intense immunosuppression and 
HSCT seem promising. Further studies are warranted in order to assess the safety of the procedure both for 
occurrence of secondary autoimmune diseases and rate of infection. Prior to considering HRCT as a novel 
and viable therapeutic option, randomized prospective trials are advised in order to determine the efficacy 
of HSCT alone and its contribution in inducing remission in SLE and APS patients.  
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First 
Author 
Year Study 
design 
Number of 
Patients 
Controls 
(if any) 
Female (n.) age (mean) transplant 
details (type) 
Indication for 
transplant 
Treatment for 
ablation 
Treatment for after 
transplant 
Phase 1 trial 
           
Traynor 
et al. 
[15] 
2000 Phase 
1 
study 
7 0 NR 27 Autologous 
HSCT 
refractory SLE CYC (200mg/kg), 
MTP (1g), and ATG 
(90mg/kg) 
3 patients were 
tapered to 5mg PDN 
daily and the other 4 
patients had their 
medication 
discontinued. 
Retrospective studies 
Loh et al. 
[16] 
2007 RS 55 (13 pts 
with 
significant 
cardiac 
abnormalities) 
0 12 of the 13 
with cardiac 
abnormalities 
39.3 (median 
age of the 13 
with cardiac 
abnormalities) 
Autologous 
HSCT 
of the 13: 
nephritis 
(n=7), 
cerebritis 
(n=8), 
refractory 
cytopenia 
(n=4), APS 
(n=8), 
pulmonary 
involvement 
(n=7), serositis 
(n=4) and 
cardiac 
dysfunction 
(n=2) 
IV CYC + 
ATG/alemtuzumab 
NR 
Vanikar 
et al. [17] 
2007 RS 27 0 24 24,2 Allogeneic 
HSCT 
NR CYC, PDN, ATG NR 
Gualandi 
et al. [18] 
2007 RS 5 0 NR NR Autologous 
BMT/HSCT 
NR BEAM + ATG No patient is taking 
over 5 mg of 
prednisone following 
transplant' 
Carrion et 
al. [19] 
2010 RS 2 0 2 22 auto-
mesenchymal 
stem cell 
transplant 
severe SLE NR NR 
 Meng et 
al. 
[20]  
2011 RS 11 39^ (all - as paper 
focuses on 
pregnancy 
outcomes) 
29 Autologous 
HSCT 
refractory SLE CYC/ATG regimen NR 
Song et 
al. 
[21]  
2011 RS 17 20 14 23 Autologous 
HSCT 
severe SLE* CYC/ATG regimen Glucocorticoids 
discontinued at 6 (12) 
or 12 months (4) 
except one patient 
who continuously 
takes prednisone 
5mg/day. 
Pasquini 
et al. [22] 
2012 RS 27 0 NR NR Autologous 
or Allogeneic 
HSCT 
NR CYC/ATG regimen NR 
Alchi et 
al. 
[23]  
2013 RS 28 0 25 29 Autologous 
HSCT 
refractory SLE low or 
intermediate 
intensity CYC/ATG 
regimen 
12 patients had an 
immunosuppressive 
drug (Cy or MMF) or 
biological agent 
introduced after 
HSCT.. PDN was 
withdrawn in 4/26 
and the 22/26 
remaining patients 
were receiving PDN 
in doses of 3-100 mg 
daily at time of last 
follow-up. 
Case reports 
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Table 1. Demographic and pre-transplant clinical characteristics of SLE patients 
 
NR, not reported; RS, retrospective study; CR, case report; ^SLE patients receiving immunosuppression therapy not transplant; CYC, 
Cyclophosphamide; MTP, methylprednisolone; PDN, prednisolone; HSCT, Hematopoietic stem cell transplantation; BMT, bone 
marrow transplantation; *SLE patients with transfusion-dependent cytopenias, severe percarditis, lung/CNS involvement or tx-
resistant glomeruloneprhtitis; ATG, Anti-thymocyte globulin; BEAM, BiCNU– carmustine, Etoposide, Ara-C – cytarabine, Melphalan; 
CBV, cyclophosphamide, BCNU (carmustine), and VP-16 (etoposide); Cy, cyclosporine; MMF,  mycophenolate; AZA, azathioprine;  
  
Euler et 
al. 
[24] 
1996 CR 1 0 1 28 Autologous 
HSCT 
Severe SLE and 
non-Hodgkin 
lymphoma 
BEAM regimen NR 
Snowden 
et al.  
[25] 
1997 CR 1 0 1 NR Autologous 
HSCT 
non-Hodgkin 
lymphoma 
CBV regimen PDN was reduced 
1mg every 3 weeks 
and then 
discontinued. Three 
years later steroid 
treatment was re-
started for  
thrombocytopenia 
Marmont 
et al. 
[26] 
1997 CR 1 0 1 46 Autologous 
HSCT 
severe 
refractory SLE 
15mg/kg Thiotepa 
/ 100mg CYC 
seven months after 
transplant 
corticosteroid 
requirement is 
10mg/daily 
Burt et al.  
[27] 
1998 CR 2 0 NR NR Autologous 
HSCT 
acute renal 
failure and 
recurrent 
alveolar 
hemorrhage 
Cymethyl-
prednisolone/ATG 
regimen 
One patient - no 
treatment, other 
patient - tapering of 
steroids 
Fouillard 
et al. [28] 
1999 CR 1 0 1 35 Autologous 
HSCT 
severe and 
progressive 
SLE 
BEAM regimen PDN reduced from 
50mg to 12.5mg 
 Brunner 
et al. [29] 
2002 CR 1 0 1 18 Autologous 
HSCT 
refractory SLE 
with 
pulmonary 
impairment 
CYC/ATG regimen NR 
Lisukov et 
al. 
[30] 
2004 CR 6 0 6 22 Autologous 
HSCT 
severe 
refractory SLE 
BEAM + ATG 
(n=2), melphalan + 
etoposid (n=2) 
and CYC/ATG 
(n=2) 
Patient 1 - oral PDN 
withdrawn after 10 
months of BMT, 
patient 2 - 
maintenance therapy 
of Cy 100mg/day, low 
dose corticosteroids 
(10-7.5mg/day) and 
AZA 50mg/day, 
patient 3- none 
mentioned) 
Talaulikar 
et al. [31] 
2005 CR 1 0 1 39 Autologous 
HSCT 
refractory SLE CYC/ATG regimen PDN 5mg daily 
Marmont 
et al. 
[32] 
2006 CR 1 0 0 26 Autologous 
HSCT 
Diffuse global 
lupus nephritis 
and refractory 
nephrotic 
syndrome with 
high 
proteinuria 
Thiotepa 10mg/kg 
followed by 
CYC100mg/kg 
5mg of PDN every 
other day 
Alexander 
et al. [33] 
2013 CR 1 0 0 21 Autologous 
HSCT 
severe 
refractory SLE 
CYC/ATG regimen immunosuppressive 
drugs withdrawn 
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     Table 2. Demographic and pre-transplant clinical characteristics of SAPS patients 
 
*8 with probable APS, 16 patients were positive for LAC, 20 for anticardiolin antibodies; **3 patients were positive for 
anticardiolin antibodies 
  
First 
Author 
Stu
dy 
des
ign 
N
# 
Pt
s 
F age 
(mea
n) 
SAPS Indication for transplant (all receiving 
Autologous HSCT with CYC/ATG 
regimen for ablation) 
Treatment for after transplant anticoagulation 
before 
transplant 
(Y/N) 
Burt 
(2006) 
[34] 
RC 50 4
3 
30 22 refractory SLE and either organ- or 
life-threatening visceral involvement 
NR Y 
Hashimo
to (2004) 
[35] 
CR 1 1 27 1 progressive myocardial damage 
caused by APS despite treatment 
low-dose corticosteroids N 
Rosen 
(2000) 
[36] 
Pha
se 
1/2 
stu
dy 
3 2 37 1 refractory SLE reduced steroid therapy (APS 
patient still on warfarin) 
Y 
Statkute 
/ Burt 
(2005) 
[37] 
RC 28 2
5 
29 28 glomerulonephritis, involvement of 
the lung or CNS, transfusion-
dependent autoimmune cytopenias, 
or APS 
8/22 remained on anti-coagulation, 
11/28 on immunosuppression and 
8/11 discontinued this within 13 
months 
Y 
Trysberg 
(2000) 
[38] 
CR 1 1 16 1 CNS lupus Cyclosporin A, low dose 
corticosteroids, azathioprine 
Y 
Musso 
(1999) 
[39] 
CR 1 1 19 1 SLE complicated by Evans' syndrome, 
severe hypercorticism and 
amenorrhoea  
NR NR 
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First 
Author 
Year Outcomes Infections Deat
hs 
other 
adverse 
events 
Follow-
up 
(month
s) 
Phase I trial 
Traynor 
et al. 
[15] 
2002 All patients demonstrated a gradual, but marked, improvement. The 
SLEDAI score has declined to <5 in 12 patients. Complement and anti–
double- stranded DNA levels have normalized and marked improvements 
in end organ function have occurred in all subjects 
10 different 
infections 
reported 
NR NR 36 
Retrospettive studies 
Loh et 
al. 
[16] 
2007 No transplant-related or cardiac deaths occurred among the 13 patients. 
Significant non-haematological toxicities included fluid overload, infection 
and engraftment syndrome. All patients with impaired LVEF remained 
stable or improved while 3 with symptomatic mitral valve disease 
similarly improved.  
NR 3* NR 24 
Vanikar 
et al. 
[17] 
2007 Average disease-free interval was 7.35 months and serology improved NR NR NR 57 
Gualand
i et al. 
[18] 
2007 All had a complete remission following transplant, but there were two 
relapses. However these both responded to Rituximab. The cumulative 
SLEDAI index dropped from 90 pre-transplant to 9 post-transplant.  
NR NR NR NR 
Carrion 
et al. 
[19] 
2010 ??? - Induces an increase of circulating T-reg cells that was not associated 
with clinical benefit 
NR 0 NR 3,5 
  
Meng 
et al. 
[20] 
2011 SLESAI scores after treatment either by transplantation or by 
immunosuppressive therapy decreased dramatically when compared to 
that before treatment, although there was no significant difference 
between the two groups. However, the rate of maternal HTN and lupus 
nephritis of mother was greatly reduced in autologous peripheral blood 
stem cell transplanted group compared to non-transplanted group. 
Additionally, the outcome of lupus flare activity of the mother after 
delivery is significantly better in transplanted group.  
9% of 
transplanted 
group and 13% 
of non-
transplanted 
group 
NR NR NR 
Song et 
al. 
[21] 
2011 progression-free survival of patients in auto-SCT group was 64.7% 
(significantly higher than control group), one female patient experienced 
a relapse after a spinal TB infection 
8 2** 4 
(allergic 
reaction 
to 
cycloph
osphami
de - 1, 
fever 
related 
to G-CSF 
- 3 and 
bone 
pain -4 )  
89 
Pasquin
i et al. 
[22] 
2012 6 deaths  NR 8 
*** 
NR 31 
Alchi et 
al. 
[23] 
2013 5 year overall survival was 81% (+/-8%), disease-free survival was 29% (+/-
9%), relapse incidence 56% (+/-11%) 
15 5 in 
2 
year
s 
afte
r 
trea
tme
nt (3 
caus
ed 
by 
infe
ctio
n, 1 
31 
severe 
or life-
threate
ning AE 
(15 
infectio
ns, one 
develop
ed 
Epstein 
Barr-
associat
ed 
lympho
38 
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prog
ressi
ve 
SLE, 
1 
seco
ndar
y 
auto
imm
une 
dise
ase) 
prolifera
tive 
disorder
, 2 
develop
ed 
seconda
ry 
autoim
mune 
disease, 
one 
autoim
mune 
haemoly
tic 
anaemia
, 1 
acquire
d 
haemop
hilia, 2 
CV 
events) 
Case report 
 
 
      
Eular et 
al. 
[24] 
1996 Complete remission of NHL and SLE but serological SLE symptoms 
persisted. On day 352 after transplant, patient showed signs of relapsing 
SLE, eventually developing severe thrombocytopenia which eventually led 
to a fatal intracerebral hemorrhage on day 378 
NR 1 NR 12 
Snowde
n et al. 
[25] 
1997 Patient went into clinical and serological remission following transplant, 
however 3 years later the patient presented with thrombocytopenia (ITP), 
which had not previously been a feature of the SKE, necessitating 
reintroduction of steroid immunosuppression. 
2 (oral herpes 
simplex, 
pneumocystis 
jirovecii 5 
months after 
transplant) 
0 angular 
chelitis 
36 
Marmo
nt et al. 
[26] 
1997 Patient obtained good partial remission, reduction in steroid requirement, 
and a  persistent negativisation of ANA 
0 0 0 7 
  
Burt et 
al. 
[27] 
1998 first patient is off all immunosuppressants for the first time in 13 years, 
second patient - hemoptysis and pulmonary infiltrates have resolved and 
steroids are gradually being tapered off.  
0 0 0 11 
Fouillar
d et al. 
[28] 
1999 One year later, the patient is in clinical remission. ANA and anti-SSA 
antibodies were undetectable at 1 and 6 months after intensification, but 
reappeared at low levels at 9 months.  
None during tx 
but once 
discharged the 
patient 
developed 
herpes simplex 
virus on day 90 
0 grade II 
mucositi
s 
12 
  
Brunner 
et al. 
[29] 
2002 21 months after the patient was still in clinical remission, with no signs of 
SLE-related disease activity and without any immunosuppressive 
medications. Her pulmonary function has also returned to normal. 
Pseudomonas 
aeruginosa 
0 0 21 
  
Lisukov 
et al. 
[30] 
2004 3 patients died on days 11,22 and 63 due to transplant related 
complications, complete remission of SLE in 2 patients after 6 months, 
other patient (with CNS lupus) had neurological improvement but 
serological SLE symptoms persist (elevated ANA, anti-dsDNA and 
anticardiolipin antibodies) and SLEDAI 2 - partial improvement 
4 (pneumonia 
x2, CMV x1, 
genital herpes 
x1) 
3 mucositi
s x3, 
enterop
athy x 3, 
severe 
haemorr
hage x2, 
sepsis 
x3 
(60 and 
6 
months 
for 2 
patients 
- 
complet
e 
remissi
21 
 
 
Table 3. Outcomes, mortality and post-transplant clinical characteristics of SLE patients 
 
* Three patients died; two from SLE progression/relapse at 11.5 months and 19 months post-transplant, respectively 
and the third folllwing an accident at 8 months; **severe pneumonia - 33 months after and heart failure - 64 months 
after; ***6 from infestations, 1 from active SLE and 1 from graft failure.  
  
on and 
42 
months 
for the  
patient 
with a 
partial 
respons
e) 
Talaulik
ar et al. 
[31] 
2005 at 12 months post-transplantation, the patient remains asymptomatic  0 0 0 12 
  
Marmo
nt et al. 
[32] 
2006 Proteinuria dropped almost immediately, serology (anti-dsDNA, ANA, 
LAC) became negative within 2 months and 5 years on the patient is well 
and active.. 
NR 0 NR 60 
  
Alexand
er et al. 
[33] 
2013 Clinical remission was achieved for SLE within 3 months after HSCT and 
anti-dsDNA antibodies disappeared despite immunosuppressive drug 
withdrawal  
NR 0 8 
months 
after 
HSCT, 
the 
patient 
present
ed with 
spontan
eous 
joint 
and skin 
bleeding 
and was 
diagnos
ed with 
factor 
VIII 
(FVIII) 
inhibitor 
haemop
hilia  
8 
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First Author Outcomes Infections Deaths Follo
w-up 
(mon
ths) 
aPL 
negativizati
on after 
transplant 
Patient 
anticoagulated 
after trasplant 
Burt 
(2006) 
[34] 
50% survived disease-free at 5 years, 84% 
survived at 5 years 
27 
infections 
during 
treatment, 
post-
discharge 
(flu) 
2 patients died 
after mobilization 
(one from 
mucormyosis and 
another from 
active lupus), 
treatment-
related mortality 
was 2% (1/50) 
29 NR 4 (18 were able to 
discontinue 
anticoagulation) 
Hashimoto 
(2004) 
[35] 
Improved clinical symptoms of APS 0 0 21 1 0 
  
Rosen 
(2000) 
[36] 
patients in remission, disease-related 
autoantibody titres declined to within the 
normal range. Corticosteroid therapy was 
gradually reduced in all patients.  
0 0 19 all 3 became 
negative  
1 
  
Statkute / 
Burt 
(2005) 
[36] 
21/28 entered remission of SLE, 9/28 were 
able to discontinue all immunosppressive 
medications from immediately to 13 
months after transplantation and stayed in 
remission from 12 to 66 months since 
stopping immunosuppression. 
9 bacterial 
infection, 2 
fungal, 3 
viral 
0    1 
Trysberg 
(2000) 
[38] 
regression of lesions in the brain and spinal 
cord 
0 0 18 
mont
hs 
negative in 
first 6 
months  
1 
  
Musso 
(1999) 
[39] 
patient alive and well, with normal blood 
counts and persistent low-titre direct anti-
globulin and ANA tests. Anti-dsDNA, LCA 
and aCL tests are all negative. No further 
treatment given. 
1 
(Pseudomon
as spp.) 
0 8 negative 0 
  
 
Table 4. Outcomes, mortality and post-transplant clinical characteristics of SAPS patients  
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Figure 1. Study selection process  
 
 
 
 
 
 
 
 
 
